Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population

KT Simms, A Keane, DTN Nguyen, M Caruana… - Nature Medicine, 2023 - nature.com
Abstract In 2020, the World Health Organization (WHO) launched a strategy to eliminate
cervical cancer as a public health problem. To support the strategy, the WHO published …

Projected association of human papillomavirus vaccination with oropharynx cancer incidence in the US, 2020-2045

Y Zhang, C Fakhry, G D'Souza - JAMA oncology, 2021 - jamanetwork.com
Importance Oropharynx cancer (OPC) incidence has increased for several decades in the
US. It is unclear when and how this trend will be affected by current HPV vaccination trends …

Estimated prevalence and incidence of disease-associated human papillomavirus types among 15-to 59-year-olds in the United States

RM Lewis, JF Laprise, JW Gargano… - Sexually transmitted …, 2021 - journals.lww.com
Methods Prevalence and incidence were estimated for infections with any HPV (any of 37
types detected using Linear Array) and disease-associated HPV, 2 types that cause …

Projected time to elimination of cervical cancer in the USA: a comparative modelling study

EA Burger, MA Smith, J Killen, S Sy… - The Lancet Public …, 2020 - thelancet.com
Summary Background In May, 2018, the Director-General of WHO issued a global call to
eliminate cervical cancer as a public health problem, which will involve ambitious screening …

Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an …

MA Smith, EA Burger, A Castanon, IMCM de Kok… - Preventive …, 2021 - Elsevier
COVID-19 has disrupted cervical screening in several countries, due to a range of policy-,
health-service and participant-related factors. Using three well-established models of …

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

JJ Kim, KT Simms, J Killen, MA Smith, EA Burger… - PLoS …, 2021 - journals.plos.org
Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …

Impact of COVID-19-related care disruptions on cervical cancer screening in the United States

EA Burger, EEL Jansen, J Killen… - Journal of medical …, 2021 - journals.sagepub.com
Objectives To quantify the secondary impacts of the COVID-19 pandemic disruptions to
cervical cancer screening in the United States, stratified by step in the screening process …

Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer

H Ni, L Zhang, H Huang, S Dai, J Li - Journal of translational medicine, 2020 - Springer
Abstract Background Methyltransferase-like 3 (METTL3) is a member of the m 6 A
methyltransferase family and acts as an oncogene in cancers. Recent studies suggest that …

[HTML][HTML] Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: a model-based analysis

A Portnoy, K Pedersen, L Trogstad, BT Hansen… - Preventive …, 2021 - Elsevier
Following the global call for action by the World Health Organization to eliminate cervical
cancer (CC), we evaluated how each CC policy decision in Norway influenced the timing of …

Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States

V Daniels, VS Prabhu, C Palmer, S Samant… - Human Vaccines & …, 2021 - Taylor & Francis
ABSTRACT The Advisory Committee on Immunization Practices (ACIP) recommended catch-
up 9-valent Human Papillomavirus (HPV) vaccination through age 26 years, and shared …